The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
Open accessAbstract
The central role of cyclin-dependent kinases (CDKs) in cell cycle regulation makes them a promising target for studying inhibitory molecules that can modify the degree of cell proliferation. The discovery of specific inhibitors of CDKs such as polyhydroxylated flavones has opened the way to investigation and design of antimitotic compounds. A novel flavone, (-)-cis-5,7-dihydroxyphenyl-8-[4-(3-hydroxy-1-methyl)piperidinyl] -4H-1-benzopyran-4-one hydrochloride hemihydrate (L868276), is a potent inhibitor of CDKs. A chlorinated form, flavopiridol, is currently in phase I clinical trials as a drug against breast tumors. We determined the crystal structure of a complex between CDK2 and L868276 at 2.33 angstroms resolution and refined to an Rfactor 20.3%. The aromatic portion of the inhibitor binds to the adenine-binding pocket of CDK2, and the position of the phenyl group of the inhibitor enables the inhibitor to make contacts with the enzyme not observed in the ATP complex structure. The analysis of the position of this phenyl ring not only explains the great differences of kinase inhibition among the flavonoid inhibitors but also explains the specificity of L868276 to inhibit CDK2 and CDC2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Dulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex
Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massagué, J., & Pavletich, N. P. (1995) · Nature · doi:10.1038/376313a0 · Cited by 1,436
ANIMAL CELL CYCLES AND THEIR CONTROL
Norbury, C., & Nurse, P. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.002301 · Cited by 1,274
Crystal structure of cyclin-dependent kinase 2
De Bondt, H. L., Rosenblatt, J., Jancarik, J., Jones, H. D., Morgan, D. O., & Kim, S.-H. (1993) · Nature · doi:10.1038/363595a0 · Cited by 976
Self-citationThe structure of protein-protein recognition sites.
Janin, J., & Chothia, C. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46181-3 · Cited by 819
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
Cited by
Delgado-Vargas, F., Jiménez, A. R., & Paredes-López, O. (2000) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690091189257 · Cited by 1,421
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Dietary agents in cancer prevention: flavonoids and isoflavonoids
Birt, D. F., Hendrich, S., & Wang, W. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00137-1 · Cited by 1,171
Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., & Schlessinger, J. (1997) · Science · doi:10.1126/science.276.5314.955 · Cited by 1,097
Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 809
De Azevedo, W. F., Leclerc, S., Meijer, L., Havlicek, L., Strnad, M., & Kim, S. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.0518a.x · Cited by 729
Self-citationHalogen atoms in the modern medicinal chemistry: hints for the drug design
Hernandes, M., Cavalcanti, S. M., Moreira, D. R., de Azevedo Junior, W., & Leite, A. C. (2010) · Current Drug Targets · doi:10.2174/138945010790711996 · Cited by 723
Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 626
Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo
Chao, S.-H., & Price, D. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102306200 · Cited by 621
Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site
Young, P. R., McLaughlin, M. M., Kumar, S., Kassis, S., Doyle, M. L., McNulty, D., Gallagher, T. F., Fisher, S., McDonnell, P. C., Carr, S. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.12116 · Cited by 570
Pharmacological inhibitors of cyclin-dependent kinases
Knockaert, M., Greengard, P., & Meijer, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02071-0 · Cited by 537
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Self-citationMeijer, L., Thunnissen, A.-M., White, A., Garnier, M., Nikolic, M., Tsai, L.-H., Walter, J., Cleverley, K., Salinas, P., Wu, Y.-Z., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00063-6 · Cited by 454
Self-citationStructural basis of inhibitor selectivity in MAP kinases
Wang, Z., Canagarajah, B. J., Boehm, J. C., Kassisà, S., Cobb, M. H., Young, P. R., Abdel-Meguid, S., Adams, J. L., & Goldsmith, E. J. (1998) · Structure · doi:10.1016/s0969-2126(98)00113-0 · Cited by 423
Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors
Traxler, P., & Furet, P. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00044-8 · Cited by 388
A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
Tong, L., Pav, S., White, D. M., Rogers, S., Crane, K. M., Cywin, C. L., Brown, M. L., & Pargellis, C. A. (1997) · Nature Structural Biology · doi:10.1038/nsb0497-311 · Cited by 387
Conseil, G., Baubichon-Cortay, H., Dayan, G., Jault, J.-M., Barron, D., & Di Pietro, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9831 · Cited by 381
Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., et al. (2001) · Genome Biology · doi:10.1186/gb-2001-2-10-research0041 · Cited by 370
Self-citationCaspase-2 Mediates Neuronal Cell Death Induced by β-Amyloid
Troy, C. M., Rabacchi, S. A., Friedman, W. J., Frappier, T. F., Brown, K., & Shelanski, M. L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-04-01386.2000 · Cited by 354
Baumli, S., Lolli, G., Lowe, E. D., Troiani, S., Rusconi, L., Bullock, A. N., Debreczeni, J. É., Knapp, S., & Johnson, L. N. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.121 · Cited by 353
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., et al. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00179-1 · Cited by 335
Molegro Virtual Docker for Docking
Bitencourt-Ferreira, G., & de Azevedo, W. F. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9752-7_10 · Cited by 331
Self-citationFlavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials
Senderowicz, A. M. (1999) · Investigational New Drugs · doi:10.1023/a:1006353008903 · Cited by 330
Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation
Sielecki, T. M., Boylan, J. F., Benfield, P. A., & Trainor, G. L. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990256j · Cited by 323
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Structure and function of Polo-like kinases
Lowery, D. M., Lim, D., & Yaffe, M. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208280 · Cited by 293
The regulation of protein phosphorylation
Johnson, L. N. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370627 · Cited by 291
Aggarwal, B. B., Ichikawa, H., Garodia, P., Weerasinghe, P., Sethi, G., Bhatt, I. D., Pandey, M. K., Shishodia, S., & Nair, M. G. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.1.87 · Cited by 286
Cyclin-dependent kinases as a therapeutic target for stroke
Osuga, H., Osuga, S., Wang, F., Fetni, R., Hogan, M. J., Slack, R. S., Hakim, A. M., Ikeda, J.-E., & Park, D. S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170144197 · Cited by 281
The structure of mitogen-activated protein kinase p38 at 2.1-Å resolution
Wang, Z., Harkins, P. C., Ulevitch, R. J., Han, J., Cobb, M. H., & Goldsmith, E. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2327 · Cited by 275
Park, D. S., Morris, E. J., Greene, L. A., & Geller, H. M. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01256.1997 · Cited by 270
Lawrie, A. M., Noble, M. E. M., Tunnah, P., Brown, N. R., Johnson, L. N., & Endicott, J. A. (1997) · Nature Structural Biology · doi:10.1038/nsb1097-796 · Cited by 268
Chang, Y.-T., Gray, N. S., Rosania, G. R., Sutherlin, D. P., Kwon, S., Norman, T. C., Sarohia, R., Leost, M., Meijer, L., & Schultz, P. G. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80048-9 · Cited by 268
Protein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
Wang, R. B., Kuo, C. L., Lien, L. L., & Lien, E. J. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00487.x · Cited by 225
Metadata
- Authors
- De Azevedo, W. F., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., & Kim, S. H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-04-02
- Volume
- 93
- Issue
- 7
- Pages
- 2735-2740
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2010992064
- Cited by
- 496
- References
- 27
- FWCI
- 26.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.